SOT CCT Meeting: The Use of Cardiomyocytes for the Assessment of Proarrhythmic Risk


                  October 25–26, 2016
                   Arlington, Virginia


The specific objectives of the workshop include:

  1. Sharing of experiences using stem cell-derived cardiomyocytes (SC-CMs) including hiPSC-CMs and embryonic stem cells-derived cardiomyocytes (hESC-CMs) for the testing of electrophysiological effects and the assessment of resultant proarrhythmic risk or other drug-induced safety risks (e.g., contractility or calcium homeostasis).
  2. Define the cell characteristics needed for use in a given assay system.
  3. Discuss in vitro assay methods and markers needed to standardize the defined phenotype of hiPSC-CM and ensure quality.
  4. Discuss the role of electrophysiological studies of cardiac myocytes to predict the proarrhythmic potential of drugs.
  5. Identify advanced uses of hiPSC-CM that can be used to identify potential cardiovascular risk.


SPS Members may attend this meeting at a discount since the Society is a Scientific Liaison Coalition (SLC) Member.

More information can be found on the workshop website.


Recent Stories
SPS Webinar: Engineering Microscale Disease Models for Heart and Skeletal Muscle - June 11

SPS 2020 Annual Meeting: COVID-19 Update

Safety Pharm Chats – Connecting Outside the Bench